| Name | Haleon |
|---|---|
| Epic | HLN |
| Isin | GB00BMX86B70 |
| Index | UK100 UK350 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 344.90p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £30,718.14 | Debt ratio | n/a |
| Shares in issue | 8,906.39 | Debt-to-equity ratio | n/a |
| P/E ratio | 23.9 | Assets / equity ratio | n/a |
| Total dividends per share | 2.20p | Price to book value | n/a |
| Dividend yield | 1.7 | ROCE | 62.31 |
| Dividend cover | 2.39 | EPS growth | 39 |
| Earning per share | 15.8 | 52-week high / low | 326.60p / 415.20p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| Interim | 2025-08-14 | 2025-09-18 | 2.20p |
| Final | 2025-04-24 | 2025-06-05 | 4.60p |
| Interim | 2024-08-15 | 2024-09-19 | 2.00p |
| Final | 2024-03-14 | 2024-05-16 | 4.20p |
| Interim | 2023-08-24 | 2023-10-05 | 1.80p |
| Final | 2023-03-16 | 2023-04-27 | 2.40p |
| Company name | Haleon |
|---|---|
| Address | Building 5, First Floor, The Heights, Weybridge, Surrey, United Kingdom, KT13 0NY |
| Telephone | +44 (0) 371 384 2227 |
| Website | https://www.haleon.com/ |
| Director | Position |
|---|---|
| Mr Brian McNamara | CEO |
| Ms Dawn Allen | CFO |
| Mr Dave Lewis | Non-Executive Chairman |
| Mr Manvinder Singh (Vindi) Banga | Senior Independent Non-Executive Director |
| Mrs Tracy Jayne Clarke | Independent Non-Executive Director |
| Miss Nancy Avila | Independent Non-Executive Director |
| Ms Dame Vivienne Cox | Independent Non-Executive Director |
| Mr Matt Shattock | Independent Non-Executive Director |
| Ms Blathnaid Bergin | Independent Non-Executive Director |
| Mr Alan Stewart | Independent Non-Executive Director |
| Mr Asmita Dubey | Independent Non-Executive Director |
| Mr Marie-Anne Aymerich | Independent Non-Executive Director |
| Assets £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Reporting date | 31/12/24 | 31/12/23 | 31/12/22 |
| Intangible asssets and goodwill | 26211 | 26855 | 28436 |
| Investments and other non-current assets | 82 | n/a | n/a |
| Total non-current assets | 28597 | 29237 | 30756 |
| Inventory / work in progress | 1190 | 1408 | 1348 |
| Trade and other receivables | 2055 | 1856 | 1977 |
| Cash and equivalents | 2250 | 1044 | 684 |
| Other current assets and asset held for resale | 223 | 114 | 50 |
| Total of all assets | 34315 | 34055 | 34815 |
| Liabilities £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Short term liabilities | 5812 | 4640 | 4370 |
| Long term liabilities | 12279 | 12686 | 13988 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 18091 | 17326 | 18358 |
| Net assets £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net assets | 16224 | 16729 | 16457 |
| Equity £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Share capital | 91 | 92 | 92 |
| Minority interests | 58 | 123 | 126 |
| Retained earnings | 27272 | 27474 | 26730 |
| Share premium account | -11197 | -10960 | n/a |
| Total equity | 16224 | 16729 | 16457 |
| Income £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | 2206 | 1996 | 1825 |
| Pre-tax profit | 1910 | 1628 | 1618 |